文献速递前列腺癌

PSA密度与前列腺多参数MRI PI-RADS评分系统互补用于临床显著前列腺癌风险分层

PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-05-06

本研究分析327例接受MR/US融合靶向前列腺穿刺活检患者的709个病灶,评估PSA密度(PSAD)与PI-RADS v2评分对临床显著前列腺癌(CSPC)的互补预测价值。PSAD与PI-RADS联合预测CSPC的AUC为0.78,高于单独PSAD的0.67和单独PI-RADS的0.72(p<0.001)。PSAD≥0.1 ng/ml/cc的截断值似乎可与PI-RADS评分互补进行CSPC风险分层。

要点

  • PSAD与PI-RADS联合预测CSPC的AUC为0.78,优于单独任一指标。
  • 控制PI-RADS评分、年龄和种族后,PSAD每增加0.01,CSPC的OR为1.03(95%CI 1.02-105,p<0.001)。
  • PSAD≥0.1 ng/ml/cc的高值与低值对CSPC的区分大致相当于PI-RADS评分增加1分。

核心结论

  • PSAD以0.1 ng/ml/cc为截断值似乎是有用的标志物,可与前列腺MP-MRI互补对CSPC进行风险分层。

研究设计与样本

  • 经IRB批准的研究,分析接受MR/US融合靶向前列腺穿刺活检患者的病理结果,共327例患者、709个病灶。
  • 按PSA、PSAD、年龄、种族和PI-RADS v2评分等参数分层,CSPC定义为Gleason评分≥7。
  • 采用逻辑回归计算OR及95%CI,P值双侧,p<0.05为统计学显著,生成ROC曲线评估预测价值并进行敏感度+特异度优化确定最佳截断值。

主要发现

  • PSAD与PI-RADS评分对CSPC诊断提供互补预测价值(AUC:PSAD 0.67,PI-RADS 0.72,联合0.78,p<0.001)。
  • 控制PI-RADS评分、年龄和种族后,多因素分析显示PSAD与CSPC独立相关(PSAD每增加0.01,OR 1.03,95%CI 1.02-105,p<0.001)。
  • PSAD≥0.1 ng/ml/cc为最佳截断值,高PSAD与低PSAD对CSPC的区分大致相当于PI-RADS评分增加1分。
  • CSPC检出情况:PI-RADS≤3且PSAD低者为4%,PI-RADS 3且PSAD高者为6%,PI-RADS 4且PSAD低者为5%,PI-RADS 4且PSAD高者为22%,PI-RADS 5且PSAD低者为29%,PI-RADS 5且PSAD高者为46%。

关键数值与推荐

  • PSAD最佳截断值为≥0.1 ng/ml/cc。
  • CSPC定义为Gleason评分≥7。
  • PI-RADS v2评分用于分层。

临床怎么用

  • 原文结论认为PSAD以0.1 ng/ml/cc为截断值似乎是有用的标志物,可与前列腺MP-MRI互补对CSPC进行风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While prostate multiparametric-magnetic resonance imaging (MP-MRI) has improved the diagnosis of clinically significant prostate cancer (CSPC), the complementary use of prostate-specific antigen (PSA) levels to risk-stratify for CSPC requires further study. The objective of this project was to determine if prostate MP-MRI and PSA can provide complementary insights into CSPC risk stratification. METHODS: In an IRB-approved study, pathologic outcomes from patients who underwent MR/US fusion-targeted prostate biopsy were stratified by various parameters including PSA, PSA density (PSAD), age, race, and PI-RADS v2 score. CSPC was defined as a Gleason score ≥7. Logistic regression was used to determine odds ratios (OR) with 95% confidence intervals (CI). P values were reported as two-sided with p < 0.05 considered statistically significant. ROC curves were generated for assessing the predictive value of tests and sensitivity + specificity optimization was performed to determine optimal testing cutoffs. RESULTS: A total of 327 patients with 709 lesions total were analyzed. PSAD and PI-RADS scores provided complementary predictive value for diagnosis of CSPC (AUC PSAD: 0.67, PI-RADS: 0.72, combined: 0.78, p < 0.001). When controlling for PI-RADS score, age, and race, multivariate analysis showed that PSAD was independently associated with CSPC (OR 1.03 per 0.01 PSAD increase, 95% CI 1.02-105, p < 0.001). The optimal cutoff of PSAD ≥ 0.1 ng/ml/cc shows that a high versus low PSAD was roughly equivalent to an increase in 1 in PI-RADS score for the presence of CSPC (4% of PI-RADS ≤3 PSAD low, 6% of PI-RADS 3 PSAD high vs. 5% of PI-RADS 4 PSAD low, 22% of PI-RADS 4 PSAD high vs. 29% of PI-RADS 5 PSAD low, 46% of PI-RADS 5 PSAD high were found to have CSPC). CONCLUSIONS: PSAD with a cutoff of 0.1 ng/ml/cc appears to be a useful marker that can stratify the risk of CSPC in a complementary manner to prostate MP-MRI.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Frisbie JW, Van Besien AJ, Lee A, et al. PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer. Prostate Cancer Prostatic Dis. 2022. PMID: 35523940. doi:10.1038/s41391-022-00549-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。